Leading Innovation in Non-animal Testing
Thank you for your interest in our participation at the LSX World Congress, where we are driving the future of non-traditional testing platforms and human-relevant models. As a leader in advancing alternative methods, we are committed to faster, more predictive, and ethical science because every moment matters.
At this global event, Charles River is showcasing how we are shaping the future of drug discovery and development by bridging scientific innovation with real-world applications. Our experts will discuss:
- Bridging Innovation and Application with Advanced Cell Models and In Silico Predictive Tools
- Accelerating Validation and Regulatory Confidence
- Driving Scaled Adoption Through Collaboration
Tuesday, September 16 | 12:00 p.m. - 12:40 p.m. EDT
New Approach Methodologies (NAMs): Challenges and Opportunities for Biotech Innovators Working to Reduce Animal Testing
Moderator: Julie Frearson, SVP, Chief Scientific Officer
Panalists: Amir Bein, Vice President Biology, Quris AI, Sara Hjuler, Director, Microphysiological Systems, Novo Nordisk, Stephen MacKinnon, Vice President, Applied Machine Learning, Recursion, Tina Morrison, Principal Consultant, Morrison Insights, LLC
A convergence of scientific advancements, societal factors, and regulatory initiatives is increasing momentum in the drug discovery and development industry to replace traditional animal testing models with in vitro and in silico alternatives. The success of these efforts will depend in large part on our industry’s ability to harness and build trust in a combination of advanced human-derived cell models and AI-driven platforms to enhance the predictability and precision of drug development. In this expert panel, KOLs will discuss the current state of these technologies, challenges to adoption, and perspectives on how their implementation will reshape drug discovery and non-clinical development.
mAb: Animal Testing vs. Alternatives
This story will delve into the rationale behind why FDA leaders chose to start with mAbs, how NAMS and other alternatives are being used, and if science is ready to meet the timetable of 1-3 years.
Read the article
Bringing Safer, Smarter Therapies to Patients Faster
Imagine a world where medicines are safer, more effective, and reach patients faster. Charles River is making that vision a reality with organoids – miniature, lab-made models of human organs that closely mimic how real organs respond to drugs.
Read the article
Have questions or want to discuss a project?
Consult an Expert